Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Tivic hits enrollment target for vagus nerve stimulation trial
Clinical Trials Arena
Sunday, November 17, 2024 - 9:30pm
tags:
Tivic Health, clinical trials, vagus nerve stimulation
How a Biogen drug set the stage for a new biotech targeting ALS
BioPharma Dive
Sunday, November 17, 2024 - 9:27pm
tags:
Biogen, Trace Neuroscience, Qalsody, ALS
Bavarian Nordic has $340 million orders for its mpox, smallpox vaccine in 2025
Yahoo/Reuters
Sunday, November 17, 2024 - 9:25pm
tags:
Bavarian Nordic, mpox, vaccines
New Alzheimer's prevention trial receives $74.5 million NIH grant
Drugs.com
Sunday, November 17, 2024 - 9:22pm
tags:
Eli Lilly, Alzheimer's disease, NIH, clinical trials
Drugmakers fall as Trump picks vaccine skeptic RFK Jr for health job
Yahoo/Reuters
Friday, November 15, 2024 - 11:35am
tags:
Robert F Kennedy Jr., Donald Trump, pharma stocks, vaccines, HHS
Survey Finds Most GLP-1 Users Discontinue Drug Before Reaching Goal Weight
Xtalks
Friday, November 15, 2024 - 11:27am
tags:
Omada Health, GLP-1 agonists, obesity, weight loss, Novo Nordisk, Eli Lilly, Ozempic, Zepbound, Mounjaro, Wegovy
Boston Pharma hits phase 2 MASH goal, positioning monthly prospect to follow Akero, 89bio into pivotal trials
Fierce Biotech
Friday, November 15, 2024 - 11:17am
tags:
Boston Pharmaceuticals, clinical trials, MASH, efimosfermin alfa
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Benzinga
Friday, November 15, 2024 - 11:15am
tags:
Regeneron, Sanofi, Dupixent, FDA, chronic spontaneous urticaria
Exact Sciences showcases early cancer detection test data at AACR meeting
Clinical Trials Arena
Friday, November 15, 2024 - 11:13am
tags:
Medtech, diagnostics, EXACT Sciences, biomarkers, cancer, MCED, AACR
Boston Sci Closes Acquisition of Medtronic’s Neuromodulation Foe
Medical Devices and Diagnostics Industry
Friday, November 15, 2024 - 11:10am
tags:
Boston Scientific, Medtech, Axonics, neuromodulation, M&A
Lilly sues US agency over blocking of drug-rebate program
MSN/Reuters
Friday, November 15, 2024 - 11:08am
tags:
Eli Lilly, 340B, HRSA, drug rebates, legal
Life science firms move ahead on AI, with concerns
Axios
Friday, November 15, 2024 - 11:07am
tags:
artificial intelligence, life sciences, R&D, drug manufacturing
Where are they now? 4 biotechs that soared then crashed during the pandemic
Pharma Voice
Friday, November 15, 2024 - 11:06am
tags:
biotech, pandemic, COVID-19, CureVac, Novavax, Inovio, Veru
How the CDC could change under the next Trump administration
NPR
Friday, November 15, 2024 - 11:04am
tags:
CDC, Donald Trump, restructuring
J&J’s nipocalimab shows promise in Phase II Sjögren’s disease trial
Clinical Trials Arena
Friday, November 15, 2024 - 11:02am
tags:
JNJ, nipocalimab, Sjögren’s syndrome
With RFK Jr. appointment for HHS, biopharma industry could face powerful adversary in government
Fierce Pharma
Thursday, November 14, 2024 - 11:11pm
tags:
Robert F Kennedy Jr., Donald Trump, HHS
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site
Fierce Biotech
Thursday, November 14, 2024 - 11:08pm
tags:
Gilead Sciences, Seattle, R&D, layoffs
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
Yahoo/Reuters
Thursday, November 14, 2024 - 11:06pm
tags:
Bristol Myers Squibb, Celgene, legal, Breyanzi
Eisai wins over European regulators on Alzheimer’s drug Leqembi
BioPharma Dive
Thursday, November 14, 2024 - 10:28pm
tags:
Eisai, Biogen, Leqembi, Alzheimer's disease
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
CP Wire
Thursday, November 14, 2024 - 10:25pm
tags:
Azurity, Danziten, Ph+ CML, FDA, Novartis, Tasigna

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.